Asian Journal of Pharmaceutical Sciences最新文献_第8页

Targeted anti-cancer therapy: Co-delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy 靶向抗癌疗法：通过 cRGD 修饰的脂质纳米颗粒联合递送血管内皮生长因子 siRNA 和异硫氰酸苯乙酯 (PEITC) 以增强抗血管生成的疗效

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-04-01 DOI: 10.1016/j.ajps.2024.100891

Bao Li , Haoran Niu , Xiaoyun Zhao , Xiaoyu Huang , Yu Ding , Ke Dang , Tianzhi Yang , Yongfeng Chen , Jizhuang Ma , Xiaohong Liu , Keda Zhang , Huichao Xie , Pingtian Ding

{"title":"Targeted anti-cancer therapy: Co-delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy","authors":"Bao Li , Haoran Niu , Xiaoyun Zhao , Xiaoyu Huang , Yu Ding , Ke Dang , Tianzhi Yang , Yongfeng Chen , Jizhuang Ma , Xiaohong Liu , Keda Zhang , Huichao Xie , Pingtian Ding","doi":"10.1016/j.ajps.2024.100891","DOIUrl":"10.1016/j.ajps.2024.100891","url":null,"abstract":"<div><p>Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target techniques, with a specific emphasis on targeting the vascular endothelial growth factor, but have not reached ideal therapeutic efficacy. In response to this issue, our study introduced a novel nanoparticle system known as CS-siRNA/PEITC&L-cRGD NPs. These chitosan-based nanoparticles have been recognized for their excellent biocompatibility and ability to deliver genes. To enhance their targeted delivery capability, they were combined with a cyclic RGD peptide (cRGD). Targeted co-delivery of gene and chemotherapeutic agents was achieved through the use of a negatively charged lipid shell and cRGD, which possesses high affinity for integrin α<sub>v</sub>β<sub>3</sub> overexpressed in tumor cells and neovasculature. In this multifaceted approach, co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) was employed to target both tumor vascular endothelial cells and tumor cells simultaneously. The co-delivery of VEGF siRNA and PEITC could achieve precise silencing of VEGF, inhibit the accumulation of HIF-1α under hypoxic conditions, and induce apoptosis in tumor cells. In summary, we have successfully developed a nanoparticle delivery platform that utilizes a dual mechanism of action of anti-tumor angiogenesis and pro-tumor apoptosis, which provides a robust and potent strategy for the delivery of anti-cancer therapeutics.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 2","pages":"Article 100891"},"PeriodicalIF":10.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087624000084/pdfft?md5=2c347081a8dbfd835d0a999ae0e2260b&pid=1-s2.0-S1818087624000084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139951662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functionalized lipid nanoparticles modulate the blood-brain barrier and eliminate α-synuclein to repair dopamine neurons 功能化脂质纳米粒子调节血脑屏障并消除α-突触核蛋白，从而修复多巴胺神经元

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-04-01 DOI: 10.1016/j.ajps.2024.100904

Xiaomei Wu , Renxiang Yuan , Yichong Xu , Kai Wang , Hong Yuan , Tingting Meng , Fuqiang Hu

{"title":"Functionalized lipid nanoparticles modulate the blood-brain barrier and eliminate α-synuclein to repair dopamine neurons","authors":"Xiaomei Wu , Renxiang Yuan , Yichong Xu , Kai Wang , Hong Yuan , Tingting Meng , Fuqiang Hu","doi":"10.1016/j.ajps.2024.100904","DOIUrl":"10.1016/j.ajps.2024.100904","url":null,"abstract":"<div><p>The challenge in the clinical treatment of Parkinson's disease lies in the lack of disease-modifying therapies that can halt or slow down the progression. Peptide drugs, such as exenatide (Exe), with potential disease-modifying efficacy, have difficulty in crossing the blood-brain barrier (BBB) due to their large molecular weight. Herein, we fabricate multi-functionalized lipid nanoparticles (LNP) Lpc-BoSA/CSO with BBB targeting, permeability-increasing and responsive release functions. Borneol is chemically bonded with stearic acid and, as one of the components of Lpc-BoSA/CSO, is used to increase BBB permeability. Immunofluorescence results of brain tissue of 15-month-old C57BL/6 mice show that Lpc-BoSA/CSO disperses across the BBB into brain parenchyma, and the amount is 4.21 times greater than that of conventional LNP. Motor symptoms of mice in Lpc-BoSA/CSO-Exe group are significantly improved, and the content of dopamine is 1.85 times (substantia nigra compacta) and 1.49 times (striatum) that of PD mice. α-Synuclein expression and Lewy bodies deposition are reduced to 51.85% and 44.72% of PD mice, respectively. Immunohistochemical mechanism studies show AKT expression in Lpc-BoSA/CSO-Exe is 4.23 times that of PD mice and GSK-3β expression is reduced to 18.41%. Lpc-BoSA/CSO-Exe could reduce the production of α-synuclein and Lewy bodies through AKT/GSK-3β pathway, and effectively prevent the progressive deterioration of Parkinson's disease. In summary, Lpc-BoSA/CSO-Exe increases the entry of exenatide into brain and promotes its clinical application for Parkinson's disease therapy.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 2","pages":"Article 100904"},"PeriodicalIF":10.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087624000217/pdfft?md5=56dd1adb8e0df656c66b5e9ef3df6cef&pid=1-s2.0-S1818087624000217-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140150703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the organelle for radiosensitization in cancer radiotherapy 在癌症放疗中以细胞器为靶点实现放射增敏

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-04-01 DOI: 10.1016/j.ajps.2024.100903

Xiaoyan Sun , Linjie Wu , Lina Du , Wenhong Xu , Min Han

{"title":"Targeting the organelle for radiosensitization in cancer radiotherapy","authors":"Xiaoyan Sun , Linjie Wu , Lina Du , Wenhong Xu , Min Han","doi":"10.1016/j.ajps.2024.100903","DOIUrl":"10.1016/j.ajps.2024.100903","url":null,"abstract":"<div><p>Radiotherapy is a well-established cytotoxic therapy for local solid cancers, utilizing high-energy ionizing radiation to destroy cancer cells. However, this method has several limitations, including low radiation energy deposition, severe damage to surrounding normal cells, and high tumor resistance to radiation. Among various radiotherapy methods, boron neutron capture therapy (BNCT) has emerged as a principal approach to improve the therapeutic ratio of malignancies and reduce lethality to surrounding normal tissue, but it remains deficient in terms of insufficient boron accumulation as well as short retention time, which limits the curative effect. Recently, a series of radiosensitizers that can selectively accumulate in specific organelles of cancer cells have been developed to precisely target radiotherapy, thereby reducing side effects of normal tissue damage, overcoming radioresistance, and improving radiosensitivity. In this review, we mainly focus on the field of nanomedicine-based cancer radiotherapy and discuss the organelle-targeted radiosensitizers, specifically including nucleus, mitochondria, endoplasmic reticulum and lysosomes. Furthermore, the organelle-targeted boron carriers used in BNCT are particularly presented. Through demonstrating recent developments in organelle-targeted radiosensitization, we hope to provide insight into the design of organelle-targeted radiosensitizers for clinical cancer treatment.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 2","pages":"Article 100903"},"PeriodicalIF":10.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087624000205/pdfft?md5=e0d13b60644e6971beba3e27b50ee960&pid=1-s2.0-S1818087624000205-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140150700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy 用于增强肿瘤化疗免疫疗法的酸性/缺氧双抑制纳米调节剂

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-04-01 DOI: 10.1016/j.ajps.2024.100905

Xiaoju Guo , Xiaoxiao Chen , Jiayi Ding , Feng Zhang , Shunyang Chen , Xin Hu , Shiji Fang , Lin Shen , Chenying Lu , Zhongwei Zhao , Jianfei Tu , Gaofeng Shu , Minjiang Chen , Jiansong Ji

{"title":"Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy","authors":"Xiaoju Guo , Xiaoxiao Chen , Jiayi Ding , Feng Zhang , Shunyang Chen , Xin Hu , Shiji Fang , Lin Shen , Chenying Lu , Zhongwei Zhao , Jianfei Tu , Gaofeng Shu , Minjiang Chen , Jiansong Ji","doi":"10.1016/j.ajps.2024.100905","DOIUrl":"10.1016/j.ajps.2024.100905","url":null,"abstract":"<div><p>Chemotherapy plays a crucial role in triple-negative breast cancer (TNBC) treatment as it not only directly kills cancer cells but also induces immunogenic cell death. However, the chemotherapeutic efficacy was strongly restricted by the acidic and hypoxic tumor environment. Herein, we have successfully formulated PLGA-based nanoparticles concurrently loaded with doxorubicin (DOX), hemoglobin (Hb) and CaCO<sub>3</sub> by a CaCO<sub>3</sub>-assisted emulsion method, aiming at the effective treatment of TNBC. We found that the obtained nanomedicine (DHCaNPs) exhibited effective drug encapsulation and pH-responsive drug release behavior. Moreover, DHCaNPs demonstrated robust capabilities in neutralizing protons and oxygen transport. Consequently, DHCaNPs could not only serve as oxygen nanoshuttles to attenuate tumor hypoxia but also neutralize the acidic tumor microenvironment (TME) by depleting lactic acid, thereby effectively overcoming the resistance to chemotherapy. Furthermore, DHCaNPs demonstrated a notable ability to enhance antitumor immune responses by increasing the frequency of tumor-infiltrating effector lymphocytes and reducing the frequency of various immune-suppressive cells, therefore exhibiting a superior efficacy in suppressing tumor growth and metastasis when combined with anti-PD-L1 (αPD-L1) immunotherapy. In summary, this study highlights that DHCaNPs could effectively attenuate the acidic and hypoxic TME, offering a promising strategy to figure out an enhanced chemo-immunotherapy to benefit TNBC patients.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 2","pages":"Article 100905"},"PeriodicalIF":10.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087624000229/pdfft?md5=389fce3d0bd5602d04c3f1574d45f07d&pid=1-s2.0-S1818087624000229-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140204319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers 用于克服生物障碍的齐聚物纳米级给药系统的最新进展

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-02-01 DOI: 10.1016/j.ajps.2023.100883

Xumei Ouyang , Yu Liu , Ke Zheng , Zhiqing Pang , Shaojun Peng

{"title":"Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers","authors":"Xumei Ouyang , Yu Liu , Ke Zheng , Zhiqing Pang , Shaojun Peng","doi":"10.1016/j.ajps.2023.100883","DOIUrl":"10.1016/j.ajps.2023.100883","url":null,"abstract":"<div><p>Nanoscale drug delivery systems (nDDS) have been employed widely in enhancing the therapeutic efficacy of drugs against diseases with reduced side effects. Although several nDDS have been successfully approved for clinical use up to now, biological barriers between the administration site and the target site hinder the wider clinical adoption of nDDS in disease treatment. Polyethylene glycol (PEG)-modification (or PEGylation) has been regarded as the gold standard for stabilising nDDS in complex biological environment. However, the accelerated blood clearance (ABC) of PEGylated nDDS after repeated injections becomes great challenges for their clinical applications. Zwitterionic polymer, a novel family of anti-fouling materials, have evolved as an alternative to PEG due to their super-hydrophilicity and biocompatibility. Zwitterionic nDDS could avoid the generation of ABC phenomenon and exhibit longer blood circulation time than the PEGylated analogues. More impressively, zwitterionic nDDS have recently been shown to overcome multiple biological barriers such as nonspecific organ distribution, pressure gradients, impermeable cell membranes and lysosomal degradation without the need of any complex chemical modifications. The realization of overcoming multiple biological barriers by zwitterionic nDDS may simplify the current overly complex design of nDDS, which could facilitate their better clinical translation. Herein, we summarise the recent progress of zwitterionic nDDS at overcoming various biological barriers and analyse their underlying mechanisms. Finally, prospects and challenges are introduced to guide the rational design of zwitterionic nDDS for disease treatment.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 1","pages":"Article 100883"},"PeriodicalIF":10.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087623001095/pdfft?md5=3e124350df384877710f4bb05396a70e&pid=1-s2.0-S1818087623001095-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139064458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Local dose-dense chemotherapy for triple-negative breast cancer via minimally invasive implantation of 3D printed devices 通过微创植入 3D 打印设备对三阴性乳腺癌进行局部剂量密集化疗

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-02-01 DOI: 10.1016/j.ajps.2024.100884

Noehyun Myung, Hyun-Wook Kang

{"title":"Local dose-dense chemotherapy for triple-negative breast cancer via minimally invasive implantation of 3D printed devices","authors":"Noehyun Myung, Hyun-Wook Kang","doi":"10.1016/j.ajps.2024.100884","DOIUrl":"10.1016/j.ajps.2024.100884","url":null,"abstract":"<div><p>Dose-dense chemotherapy is the preferred first-line therapy for triple-negative breast cancer (TNBC), a highly aggressive disease with a poor prognosis. This treatment uses the same drug doses as conventional chemotherapy but with shorter dosing intervals, allowing for promising clinical outcomes with intensive treatment. However, the frequent systemic administration used for this treatment results in systemic toxicity and low patient compliance, limiting therapeutic efficacy and clinical benefit. Here, we report local dose-dense chemotherapy to treat TNBC by implanting 3D printed devices with time-programmed pulsatile release profiles. The implantable device can control the time between drug releases based on its internal microstructure design, which can be used to control dose density. The device is made of biodegradable materials for clinical convenience and designed for minimally invasive implantation via a trocar. Dose density variation of local chemotherapy using programmable release enhances anti-cancer effects <em>in vitro</em> and <em>in vivo</em>. Under the same dose density conditions, device-based chemotherapy shows a higher anti-cancer effect and less toxic response than intratumoral injection. We demonstrate local chemotherapy utilizing the implantable device that simulates the drug dose, number of releases, and treatment duration of the dose-dense AC (doxorubicin and cyclophosphamide) regimen preferred for TNBC treatment. Dose density modulation inhibits tumor growth, metastasis, and the expression of drug resistance-related proteins, including p-glycoprotein and breast cancer resistance protein. To the best of our knowledge, local dose-dense chemotherapy has not been reported, and our strategy can be expected to be utilized as a novel alternative to conventional therapies and improve anti-cancer efficiency.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 1","pages":"Article 100884"},"PeriodicalIF":10.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087624000011/pdfft?md5=7bbad6db8cc2163ee872827bb537c50b&pid=1-s2.0-S1818087624000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139465273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spatiotemporal transformable nano-assembly for on-demand drug delivery to enhance anti-tumor immunotherapy 用于按需给药的时空可变纳米组件，增强抗肿瘤免疫疗法

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-02-01 DOI: 10.1016/j.ajps.2024.100888

Chenglin Liang, Ge Zhang, Linlin Guo, Xinyi Ding, Heng Yang, Hongling Zhang, Zhenzhong Zhang, Lin Hou

{"title":"Spatiotemporal transformable nano-assembly for on-demand drug delivery to enhance anti-tumor immunotherapy","authors":"Chenglin Liang, Ge Zhang, Linlin Guo, Xinyi Ding, Heng Yang, Hongling Zhang, Zhenzhong Zhang, Lin Hou","doi":"10.1016/j.ajps.2024.100888","DOIUrl":"10.1016/j.ajps.2024.100888","url":null,"abstract":"<div><p>Induction of tumor cell senescence has become a promising strategy for anti-tumor immunotherapy, but fibrotic matrix severely blocks senescence inducers penetration and immune cells infiltration. Herein, we designed a cancer-associated fibroblasts (CAFs) triggered structure-transformable nano-assembly (HSD-P@V), which can directionally deliver valsartan (Val, CAFs regulator) and doxorubicin (DOX, senescence inducer) to the specific targets. In detail, DOX is conjugated with hyaluronic acid (HA) via diselenide bonds (Se-Se) to form HSD micelles, while CAFs-sensitive peptide is grafted onto the HSD to form a hydrophilic polymer, which is coated on Val nanocrystals (VNs) surface for improving the stability and achieving responsive release. Once arriving at tumor microenvironment and touching CAFs, HSD-P@V disintegrates into VNs and HSD micelles due to sensitive peptide detachment. VNs can degrade the extracellular matrix, leading to the enhanced penetration of HSD. HSD targets tumor cells, releases DOX to induce senescence, and recruits effector immune cells. Furthermore, senescent cells are cleared by the recruited immune cells to finish the integrated anti-tumor therapy. <em>In vitro</em> and <em>in vivo</em> results show that the nano-assembly remarkably inhibits tumor growth as well as lung metastasis, and extends tumor-bearing mice survival. This work provides a promising paradigm of programmed delivering multi-site nanomedicine for cancer immunotherapy.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 1","pages":"Article 100888"},"PeriodicalIF":10.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087624000059/pdfft?md5=4dadab8a85a615415f3f04021f25a240&pid=1-s2.0-S1818087624000059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139816793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hydrogen sulfide responsive nanoplatforms: Novel gas responsive drug delivery carriers for biomedical applications 硫化氢响应纳米平台：用于生物医学应用的新型气体响应性给药载体

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-02-01 DOI: 10.1016/j.ajps.2023.100858

Jiafeng Zou , Zeting Yuan , Xiaojie Chen , You Chen , Min Yao , Yang Chen , Xiang Li , Yi Chen , Wenxing Ding , Chuanhe Xia , Yuzheng Zhao , Feng Gao

{"title":"Hydrogen sulfide responsive nanoplatforms: Novel gas responsive drug delivery carriers for biomedical applications","authors":"Jiafeng Zou , Zeting Yuan , Xiaojie Chen , You Chen , Min Yao , Yang Chen , Xiang Li , Yi Chen , Wenxing Ding , Chuanhe Xia , Yuzheng Zhao , Feng Gao","doi":"10.1016/j.ajps.2023.100858","DOIUrl":"10.1016/j.ajps.2023.100858","url":null,"abstract":"<div><p>Hydrogen sulfide (H<sub>2</sub>S) is a toxic, essential gas used in various biological and physical processes and has been the subject of many targeted studies on its role as a new gas transmitter. These studies have mainly focused on the production and pharmacological side effects caused by H<sub>2</sub>S. Therefore, effective strategies to remove H<sub>2</sub>S has become a key research topic. Furthermore, the development of novel nanoplatforms has provided new tools for the targeted removal of H<sub>2</sub>S. This paper was performed to review the association between H<sub>2</sub>S and disease, related H<sub>2</sub>S inhibitory drugs, as well as H<sub>2</sub>S responsive nanoplatforms (HRNs). This review first analyzed the role of H<sub>2</sub>S in multiple tissues and conditions. Second, common drugs used to eliminate H<sub>2</sub>S, as well as their potential for combination with anticancer agents, were summarized. Not only the existing studies on HRNs, but also the inhibition H<sub>2</sub>S combined with different therapeutic methods were both sorted out in this review. Furthermore, this review provided in-depth analysis of the potential of HRNs about treatment or detection in detail. Finally, potential challenges of HRNs were proposed. This study demonstrates the excellent potential of HRNs for biomedical applications.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 1","pages":"Article 100858"},"PeriodicalIF":10.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087623000855/pdfft?md5=22e01692eefc141a27c5db32e0929ab5&pid=1-s2.0-S1818087623000855-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135963308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of biomedical hydrogels for rheumatoid arthritis treatment 开发治疗类风湿性关节炎的生物医学水凝胶

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-02-01 DOI: 10.1016/j.ajps.2024.100887

Mirza Muhammad Faran Ashraf Baig , Lee Ki Wong , Abdul Wasy Zia , Hongkai Wu

{"title":"Development of biomedical hydrogels for rheumatoid arthritis treatment","authors":"Mirza Muhammad Faran Ashraf Baig , Lee Ki Wong , Abdul Wasy Zia , Hongkai Wu","doi":"10.1016/j.ajps.2024.100887","DOIUrl":"10.1016/j.ajps.2024.100887","url":null,"abstract":"<div><p>Rheumatoid Arthritis (RA) is an autoimmune disorder that hinders the normal functioning of bones and joints and reduces the quality of human life. Every year, millions of people are diagnosed with RA worldwide, particularly among elderly individuals and women. Therefore, there is a global need to develop new biomaterials, medicines and therapeutic methods for treating RA. This will improve the Healthcare Access and Quality Index and also relieve administrative and financial burdens on healthcare service providers at a global scale. Hydrogels are soft and cross-linked polymeric materials that can store a chunk of fluids, drugs and biomolecules for hydration and therapeutic applications. Hydrogels are biocompatible and exhibit excellent mechanical properties, such as providing elastic cushions to articulating joints by mimicking the natural synovial fluid. Hence, hydrogels create a natural biological environment within the synovial cavity to reduce autoimmune reactions and friction. Hydrogels also lubricate the articulating joint surfaces to prevent degradation of synovial surfaces of bones and cartilage, thus exhibiting high potential for treating RA. This work reviews the progress in injectable and implantable hydrogels, synthesis methods, types of drugs, advantages and challenges. Additionally, it discusses the role of hydrogels in targeted drug delivery, mechanistic behaviour and tribological performance for RA treatment.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 1","pages":"Article 100887"},"PeriodicalIF":10.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087624000047/pdfft?md5=ee47f049e37fdfb9bb0c42d107c9fdff&pid=1-s2.0-S1818087624000047-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139772362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design of pH-responsive antimicrobial peptide melittin analog-camptothecin conjugates for tumor therapy 设计用于肿瘤治疗的 pH 响应型抗菌肽美利汀类似物-喜树碱共轭物

IF 10.2 1区医学

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-02-01 DOI: 10.1016/j.ajps.2024.100890

Sujie Huang , Yuxuan Gao , Ling Ma , Bo Jia , Wenhao Zhao , Yufan Yao , Wenyuan Li , Tongyi Lin , Rui Wang , Jingjing Song , Wei Zhang

{"title":"Design of pH-responsive antimicrobial peptide melittin analog-camptothecin conjugates for tumor therapy","authors":"Sujie Huang , Yuxuan Gao , Ling Ma , Bo Jia , Wenhao Zhao , Yufan Yao , Wenyuan Li , Tongyi Lin , Rui Wang , Jingjing Song , Wei Zhang","doi":"10.1016/j.ajps.2024.100890","DOIUrl":"10.1016/j.ajps.2024.100890","url":null,"abstract":"<div><p>Melittin, a classical antimicrobial peptide, is a highly potent antitumor agent. However, its significant toxicity seriously hampers its application in tumor therapy. In this study, we developed novel melittin analogs with pH-responsive, cell-penetrating and membrane-lytic activities by replacing arginine and lysine with histidine. After conjugation with camptothecin (CPT), CPT-AAM-1 and CPT-AAM-2 were capable of killing tumor cells by releasing CPT at low concentrations and disrupting cell membranes at high concentrations under acidic conditions. Notably, we found that the C-terminus of the melittin analogs was more suitable for drug conjugation than the N-terminus. CPT-AAM-1 significantly suppressed melanoma growth <em>in vivo</em> with relatively low toxicity. Collectively, the present study demonstrates that the development of antitumor drugs based on pH-responsive antimicrobial peptide-drug conjugates is a promising strategy.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 1","pages":"Article 100890"},"PeriodicalIF":10.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1818087624000072/pdfft?md5=59efcad53fe7a733fb8f6be5e7c5ad6e&pid=1-s2.0-S1818087624000072-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139880805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0